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Melatonin and its metabolites 
protect human melanocytes 
against UVB-induced damage: 
Involvement of NRF2-mediated 
pathways
Zorica Janjetovic1,2, Stuart G. Jarrett3, Elizabeth F. Lee2, Cory Duprey2, Russel J. Reiter4 & 
Andrzej T. Slominski  1,2,5,6
Ultraviolet light (UV) is an inducer of reactive oxygen species (ROS) as well as 6-4-photoproducts 
and cyclobutane pyrimidine dimers (CPD) in the skin, which further cause damage to the skin cells. 
Irradiation of cultured human melanocytes with UVB stimulated ROS production, which was reduced in 
cells treated with melatonin or its metabolites: 6-hydroxymelatonin (6-OHM), N1-acetyl-N2-formyl-5-
methoxykynuramine (AFMK), N-acetylserotonin (NAS), and 5-methoxytryptamine (5-MT). Melatonin 
and its derivatives also stimulated the expression of NRF2 (nuclear factor erythroid 2 [NF-E2]-related 
factor 2) and its target enzymes and proteins that play an important role in cell protection from different 
damaging factors including UVB. Silencing of NRF2 using siRNA diminished the protective effects 
of melatonin, while the membrane melatonin receptors (MT1 or MT2) did not change the activities 
of either melatonin or its derivatives. Melatonin and its metabolites enhanced the DNA repair in 
melanocytes exposed to UVB and stimulated expression of p53 phosphorylated at Ser-15. In conclusion, 
melatonin and its metabolites protect melanocytes from UVB-induced DNA damage and oxidative 
stress through activation of NRF2-dependent pathways; these actions are independent of an effect on 
the classic membrane melatonin receptors. Thus, melatonin and its derivatives can serve as excellent 
protectors of melanocytes against UVB-induced pathology.
Exposure of the skin to ultraviolet radiation (UVR), especially UVB (290–320 nm), absorbed mainly in the epi-
dermis, induces direct DNA damage1 as cyclobutane pyrimidine dimers (CPD) and pyrimidine photoproducts 
(6–4)PPs2, 3 with additional production of reactive oxygen species (ROS)4. Collectively, these changes have detri-
mental effects that include carcinogenesis, cell senescence and other skin pathologies. While nucleotide excision 
repair (NER) mechanism is responsible for a repair of photoproducts, removal of ROS or converting them to a 
less toxic product depends on enzymes and proteins including: heme-oxygenase, glutathione peroxidase, cata-
lase, gluthatione, etc.5. The enzymes and proteins responsible for antioxidative response are under the control of 
nuclear factor erythroid 2 –like 2 (NRF2). In response to oxidative stress and ROS, NRF2 is released from Keap 
(Kelch- like ECH-associated protein), translocates to the nucleus, binds to ARE (anti-oxidant response element) 
and further activates detoxifying enzymes6.
Due to their constant exposure to oxidative stress caused by different environmental factors, skin cells express 
high levels of NRF2 that protects the skin7. NRF2 activation has been a target in treatment of many chronic dis-
eases8. Melanocytes produce melanin that protects the skin from deleterious effects of UV. Studies suggest that 
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the susceptibility of melanocytes to oxidative damage is increased due to active melanogenesis9 and increased 
levels of ROS10.
Melatonin (N-acetyl-5-methoxytryptamine) protects keratinocytes from detrimental UV radiation11 and a 
plethora of other mammalian cells against oxidative stress12–14. Melatonin a is produced primarily in pineal gland 
and retina15, but also at extrapineal sites16, including human skin17, 18 and other peripheral organs19. Melatonin, 
in addition of modulating circadian rhythms20, also exhibits antioxidant, anti-inflammatory, antiproliferative 
and prodifferentiation activities21, 22. Melatonin actions are mediated through its cognate membrane bound type 
1 and 2 (MT1 and MT2) receptors or through receptor-independent mechanisms23. Metabolites of melatonin 
can also function as potent antioxidants24 or pro-oxidants25. They also act as free radical scavengers or inducers 
of anti-oxidative enzymes12, 13, 26. Indolic, kynurenic, and classical pathways are described as the main pathways 
of melatonin metabolism12, 17, 27 and can also be produced in skin under UVB exposure28. N-acetylserotonin 
(NAS) is produced from serotonin and serves as a melatonin precursor29, 30, but it is also a melatonin metab-
olite17. N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) is produced from melatonin via kynuric path-
way12, 27, through interaction with H2O226, 31, or due to UVB exposure26. Melatonin metabolites also include 
6-Hydroxymelatonin (6-OHM) and 5-methoxytryptamine (5-MT) produced via classical or indolic pathway, 
respectively11.
Since melatonin can affect the phenotype of normal human melanocytes32, herein we tested whether its 
direct or indirect activities include protection of epidermal melanocytes against UVB-induced damage. Potential 
receptor-mediated and independent mechanism of action were also evaluated. Since it was proposed that NRF2 
acts as a master regulator of antioxidative responses and protection against UV6, we investigated whether pro-
tective effects of melatonin and its metabolites in human melanocytes are mediated through activation of NRF2.
Results
Melatonin and its metabolites protect melanocytes from UVB- induces oxidative stress. Skin 
cells exposed to UVB produce ROS and suffer DNA damage4. Melatonin can prevent the harmful effects of UVB 
on keratinocytes33, as do melatonin metabolites: AFMK, 5-MT, 6-OHM and NAS24. We assessed the protection 
from oxidative stress and antioxidative defence mechanisms in cells treated with melatonin or its metabolites 
that were irradiated with UVB intensities of 25 or 50 mJ/cm2; this dose does not significantly affect the survival 
of melanocytes34. Melatonin protects cells from toxic effects of NO35 or H2O231. To evaluate the protective effects 
against oxidative damage, normal human epidermal melanocytes (HEMn) were treated with melatonin or its 
metabolites for 24 h. After incubation, cells were exposed to UVB intensities of 0 or 25 mJ/cm2 and NO or H2O2 
were recorded 30 min later. Figure 1 shows significant reductions in NO (a) and H2O2 (b) directly produced in 
UVB-irradiated cells treated with melatonin or its metabolites; melatonin and its derivatives had similar protec-
tive actions. Non-irradiated cells showed no changes in NO or H2O2 when compared to control (Fig. 1a and b), 
while the levels of both NO or H2O2, increased in irradiated cells (Fig. 1. inserts a and b). Melatonin, 6-OHM 
and 5-MT were the strongest NO reducers, followed by AFMK and NAS. All metabolites showed similar effects 
as inhibitors of H2O2. GSH levels are lowered following UVB irradiation36, which was thwarted by melatonin, 
as described in human vascular endothelial cells37 and keratinocytes24. Melatonin or its metabolites were added 
to the melanocytes before the irradiation. The levels of GSH were recorded 1 h after the cells were exposed to 
UVB. As shown in Fig. 1c (insert), a UVB intensity of 25 mJ/cm2 did not significantly reduce the level of GSH 
as anticipated, because of the melanogenic activity of melanocytes. Melanin synthesis in melanocytes consumes 
cysteine38, which is also an important component of GSH; therefore under the influence of UVB there is an inad-
equate response in terms of oxidative damage thereby preserving GSH levels in melanocytes9. However, relative 
GSH levels rose after treatment with melatonin, AFMK or 6-OHM, while 5-MT and NAS had no effect on GSH 
in UVB exposed cells (Fig. 1c).
Melatonin and its metabolites reduce UVB- induced DNA damage in melanocytes. UVB 
induces DNA damage in cells. The DNA repair capacity of melatonin and its metabolites was measured as a 
reduction in CPDs in HEMn exposed to UVB. Immediately after irradiation, cells were treated with melatonin 
or its derivatives. CPD-positive cells were labelled with CPD-specific antibody and scored under the micro-
scope. As shown in Fig. 2a, UVB irradiation increased production of CPD (Fig. 2, inserted pictures). Treatment 
with melatonin or its metabolites caused obvious reduction of CPD levels in cells exposed to UVB 25 mJ/cm2 
(Fig. 2c) or 50 mJ/cm2 (Fig. 2d); this contrasted with the lack of such an effect in control cells (Fig. 2b). Melatonin 
reduced CPD levels by approximately 40%. While 5-MT and NAS showed a potency similar to melatonin in cells 
exposed to 25 mJ/cm2, a slightly weaker effect was noted in cells exposed to 50 mJ/cm2. AFMK and 6-OHM were 
somewhat less potent than melatonin, but still effective. To confirm the above findings we used comet assay as 
previously described39. Thus, we exposed cells to 200 mJ/cm2 UVB; to measure the protective effects of melatonin 
and its metabolites we treated cells with the mentioned compounds 24 h before the exposure to UVB and for an 
additional 3 h after. Melatonin, AFMK, 6-OHM, 5-MT and NAS all significantly reduced the tail moment of the 
comet images (p < 0.001) in comparison to the non-treated cells (Fig. 2e).
UVB induces tumor suppressor factor p53, as a response to DNA damage40. P53 further accumulates in the 
nucleus and activates the DNA repair process41. Melatonin is known to induce phosphorylation of p53 at Ser-1542, 43, 
thus activating p53. We tested the ability of melatonin and its metabolites to induce p53 phosphorylation at Ser-15 
as a response to UVB damage in comparison to melatonin. Melanocytes were treated for 3 h with melatonin or 
its metabolites after UVB exposure. All molecules tested significantly enhanced the expression of Ser-15 phos-
phorylated p53 (Fig. 3). The intensity of UVB was directly proportional to p53 accumulation (Fig. 3 inserts). 
Melatonin enhanced the p53 rise in cells exposed to 25 mJ/cm2 of UVB; p53 more than doubled with melatonin 
having the most robust effect of all metabolites, although metabolites were also potent (Fig. 3a). The induction 
of p53 under the influence of melatonin, AFMK and 6-OHM was also detected at higher UVB intensity, but to 
www.nature.com/scientificreports/
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a lesser extent (Fig. 3b). In contrast, 5-MT and NAS failed to augment the expression of Ser-15 p53 under the 
described conditions (Fig. 3b).
To further interrogate the role of melatonin and its metabolites to directly impact nucleotide excision repair 
(NER), we utilized a technique termed Oligonucleotide retrieval immunoprecipitation (ORiP)44. The ORiP assay 
relies on UV exposure or mock treatment of cells, isolation of nuclear fractions, incubation with a biotinylated 
oligonucleotide construct containing a UV-damaged fragment, retrieval of the oligonucleotide by streptavidin 
and identification of bound proteins. Nuclear fractions isolated from UV-damaged cells demonstrated binding 
of NER complex containing two core factors of this repair pathway: Xeroderma pigmentosum, complementation 
Figure 1. Melatonin, NAS, 6-OHM, AFMK, and 5-MT reduce UVB-induced oxidative stress. UVB-irradiated 
(25 mJ/cm2) and non-irradiated melanocytes (comparison presented as inserts) were treated with melatonin 
or its metabolites for 24 h prior UV irradiation at the concentration 5 × 10−5 M. NO-(a) or H2O2 (b) produced 
in melanocytes were determined 30 min after UVB irradiation, while GSH levels (c) were determined 1 h post 
UVB. Data were analyzed using student t-test, *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 1274  | DOI:10.1038/s41598-017-01305-2
group C (XPC) and Xeroderma pigmentosum, complementation group A (XPA) proteins to photoproduct 
containing-substrate (Fig. 4). Further, pre-treatment of either melatonin or one of its metabolites significantly 
enhanced the XPC and XPA interactions with the DNA substrate (compared to UV treatment alone; P ≤ 0.05) 
with both treatments of 25 mJ/cm2 or 50 mJ/cm2 of UVB (Fig. 4). These results indicate that melatonin and its 
metabolites can induce repair of DNA damaged by UVB in HEMn.
Melatonin and melatonin metabolites antioxidative properties are MT receptor independ-
ent. Melatonin and its metabolites serve as local antioxidants under oxidative stress conditions caused by 
various environmental factors, including UVR11. The exposure to UV promotes the expression of MT1 and MT2 
melatonin receptors in skin11, 45, 46. Hence, we evaluated whether melatonin’s protective effects are mediated by 
membrane bound melatonin receptors. HEMn were treated with melatonin or its metabolites at different concen-
trations in the absence or presence of luzindole, a melatonin receptor antagonist47. Melatonin and its metabolites 
exerted protective effects against UVB (50 mJ/cm2) induced ROS formation even in the presence of luzindole 
(Fig. 5). The effects of melatonin, AFMK and NAS were dose depended, being more pronounced at the higher 
Figure 2. Melatonin, NAS, 6-OHM, AFMK, and 5-MT exhibit repair capacities in UVB-induced DNA damage 
in treated melanocytes as shown by reduced levels of CPD and comet cell tail moments. Cells were treated with 
melatonin or its metabolites for 24 h prior UV irradiation at the concentration 5 × 10−5 M, further exposed 
to UVB intensities of 25 or 50 mJ/cm2 and immediately treated again with melatonin or its derivatives for 3 h. 
Cells were fixed and stained with anti-CPD antibody and further imaged with a fluorescence microscope. 
Fluorescence intensity was analysed using ImageJ software and data were analysed using Graph Pad Prizm. 
CPD formation under different UVB intensity levels are shown in (a). Figure presents CPD levels after 0 mJ/
cm2 (b), 25 mJ/cm2 (c) and 50 mJ/cm2 (d). Data are presented as percentile of control and were analyzed using 
t- test, *p < 0.05, **p < 0.01. As an example, images of the melanocytes stained with CPD antibody (green) and 
nuclear staining with propidium iodine (red) show no CPD signal in non-irradiated melanocytes (UV−) and 
positive CPD signal in UVB (25 mJ/cm2) irradiated cells (UV+) (magnification 20x). Also, melanocytes were 
treated with melatonin or its metabolites before and after UV irradiation (200 mJ/cm3). Tail moment is an index 
of DNA damage. Data are analysed using student t-test and p < 0.001 for all conditions (e).
www.nature.com/scientificreports/
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concentration (Fig. 5a and b). Melatonin and AFMK significantly decreased ROS levels at different concentra-
tions, 5 × 10−5 M (p < 0.01) (a) and 1 × 10−6 M (p < 0.05) (b). Other metabolites, 6-OHM and 5-MT showed no 
concentration dependency (p < 0.01), while NAS had an effect on ROS only at 5 × 10−5 M. The protective effects 
of melatonin and its metabolites at concentrations (5 × 10−5 M or 1 × 10−6 M) were not affected by luzindole 
(Fig. 5c and d). To corroborate whether or not the antioxidative effects of melatonin and its metabolites are 
membrane bound receptor independent, we tested the levels of both melatonin receptors (MT1 and MT2). The 
results showed very low levels of MT receptors in melanocytes. Their detection required immunoprecipitation of 
the antigen prior Western blot analysis, which otherwise was negative when whole extracts were probed with the 
antibodies (Supplementary Fig. S1).
Melatonin and its metabolites induce the expression of antioxidative enzymes in melano-
cytes. To further evaluate the status of oxidative stress in UVB irradiated melanocytes we examined the 
expression of major antioxidant enzymes, including catalase (CAT), glutathione peroxidase (GPx), glutathione 
reductase (GR), glutathione-S-transferase (GSTP1), superoxide dismutase (Cu/Zn-Sod and Mn-SOD), glutam-
ylcysteine synthetase (GCS), and NAD(P)H dehydrogenase, quinine 2 (NQO2) in melanocytes. As shown in 
Supplementary Fig. S2, at the RNA level, melatonin and its metabolites induced antioxidant enzymes after cells 
were exposed to UVB. The stimulation was dependent on the intensity of UVB; the stronger the intensity of UVB 
the greater were the effects of melatonin or its metabolites. The NRF2 transcription factor induces antioxidant 
genes; therefore, we have tested the expression of NRF2 and other related genes (HO-1, GCS and GSTP1) relative 
to the protective of melatonin or its metabolites in response to UVB induced oxidative stress. Melatonin exhibited 
a discernible effect on NRF2 expression. NRF2 levels were 4–5 fold higher in cells treated with melatonin regard-
less of UVB treatment. All other metabolites were also strong NRF2 inducers (4–6 times when compared to con-
trol), while 5-MT was somewhat more potent than the others. As anticipated, HO-1, was also strongly induced 
by melatonin or its metabolites after treatment with UVB. Melatonin induced HO-1 levels remarkably 65 times 
or 4 times when compared to control after treatment with 75 mJ/cm2 or 50 mJ/cm2, while no effect was observed 
after 25 mJ/cm2. Surprisingly, the levels of HO-1 dropped after treatment with melatonin in cells not exposed 
to UVB. GCS levels were strongly induced after treatment with melatonin or its metabolites in UVB-irradiated 
cells (Supplementary Fig. S2). The levels of GCS ranged from 15–35 times more when compared to control in 
cells treated with 75 mJ/cm2 UVB, with melatonin being the most potent. A 3–5-fold increase in GSC levels were 
detected after treatment with 50 mJ/cm2 of UVB, with NAS being more potent then melatonin or other metabo-
lites. Similarly, GSTP1 levels were also strongly induced by melatonin and metabolites (Supplementary Fig. S2).
Figure 3. UVB irradiation intensifies p53 levels. Melatonin, NAS, 6-OHM, AFMK, and 5-MT treated 
HEMn elevated levels of p53 phosphorylated at Serine 15 after UVB exposure. Melanocytes were treated with 
melatonin or its metabolites for 24 h before UVB exposure. Cells were exposed to UVB intensities of 25 (a), 
or 50 mJ/cm2 (b) and immediately treated again with melatonin or its derivatives for 12 h. Cells were further 
fixed and stained with anti-phosphorylated p53S15 antibody. Stained cells were imaged with a fluorescence 
microscope; fluorescence intensity was analysed using ImageJ software. P53 levels increased proportional to 
UVB intensity (insert). Data are analysed using Graph Pad Prizm. Data are presented as percentile of control 
and were analyzed using t- test, *p < 0.05, **p < 0.01, ***p < 0.001.
www.nature.com/scientificreports/
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Melatonin protective action from oxidative is through NRF2 pathway. To investigate the potential 
mechanism of melatonin in protection from oxidative stress caused by UVB in connection to NRF2, we used 
NRF2 interfering RNA (NRF2 siRNA) to downregulate NRF2 expression. Figure 6a shows the RT-PCR results 
indicating that mRNA level of NRF2 in cells was reduced to more than half in comparison to control. Cells were 
also treated with melatonin. Although we have shown that melatonin induces NRF2 (Supplementary Fig. 2), 
the silencing of NRF2 abrogated the effects of melatonin, while cells treated with scrambled siRNA showed no 
change in NRF2 mRNA (Fig. 6a) or protein levels (Fig. 6 insert). To determine whether antioxidative genes down-
stream of NRF2-ARE pathway are affected by silencing of NRF2, we examined the HO-1 and NQO2 on mRNA. 
Figure 6 shows the reduction of the main phase II detoxifying enzymes: HO-1 (b) and NQO2 (c) in the cells after 
silencing NFR2 and treatment with melatonin when compared to scrambled siRNA. Immunofluorescent anal-
ysis on melanocytes treated with melatonin or its metabolites after exposure to UVB revealed greater intensity 
of NRF2 in comparison to non-irradiated cells (Fig. 7). Melatonin and NAS slightly enhanced NRF2 expression 
in non-irradiated cells (Fig. 7a), but all metabolites induced NRF2 after UVB exposure more than double when 
compared to control (Fig. 7b), with NAS having the strongest influence. Cells exposed to UVB showed reduction 
in NRF2 levels (Fig. 7 insert), which is in accordance with previous reports48.
Figure 4. Melatonin and its metabolites enhance the XPC- and XPA-DNA-interaction. Melanocytes were 
treated with melatonin or its metabolites for 24 h in complete melanocyte medium. Cells were further exposed 
to either (a) non UVB-treated (0 mJ/cm2) or (b) 25 mJ/cm2 or (c) 50 mJ/cm2. Synthetic oligonucleotides 
(Molecular Beacons) were assembled to form 5′-biotinylated duplex DNA fragment. The substrate provides 
a substrate for NER proteins and DNA-protein interactions were determined using anti-XPC and anti-XPA 
antibodies as described in the Methods. Treatments significantly different from vehicle were determined by one-
way ANOVA; *p ≤ 0.05. All treatments in B or C were statistically significant when compared to vehicle.
www.nature.com/scientificreports/
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Figure 5. Melatonin, NAS, 6-OHM, AFMK, and 5-MT reduce levels of ROS produced in UVB-irradiated 
melanocytes. Cells were treated without (a,b) or with (c,d) luzindole 1 h prior treatment with melatonin, 
AFMK, 6-OHT, 5-MT, NAS, or EtOH for 1 h at the concentrations of 5 × 10−5 M (a,c) or 1 × 10−6 M (b,d). CM-
H2DCFDA dye was added to the cells for 30 min and cells are further irradiated with 50 mJ/cm2 of UVB. ROS 
levels in melanocytes were determined 30 min after UVB irradiation. The differences in H2O2 production under 
different UVB intensities are shown as insert. Data are presented as percent of control and were analyzed using 
t-test, *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 6. Silencing of the NRF2 in human melanocytes reduced the effect of melatonin on the expression 
of NRF2 and NRF2-related genes: HO-1 and NQO2. Melanocytes were transfected with scrambled or NRF2 
siRNA and treated with 5 × 10−5 M melatonin. Cells were lysed after treatment and total RNA extracted. NRF2 
mRNA (a), HO-1 mRNA (b) and NQO2 (c) levels were measured using reagents for RTPCR and normalized 
relative to B-actin RNA. Levels of NRF2 and B-actin were assessed 72 h after transfection with NRF2 or 
scrambled siRNA, by western blotting of whole-cell extracts (insert).
www.nature.com/scientificreports/
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Discussion
Skin and skin cells are under the constant influence of different environmental stressors, including UVB, which 
can induce formation of reactive oxygen species (ROS) and cause oxidative damage4, 49. The damage to the skin 
results in cell senescence, photoaging, carcinogenesis, inflammation, etc. Increased levels of ROS after exposure 
to UVB has toxic effects on melanocytes, as described in vitiligo50. Natural compounds, such as melatonin, have 
the potential of activating endogenous antioxidants defence mechanisms and enhancing protection of skin from 
UV12. Melatonin is antioxidant and a free radicals scavenger14; it detoxifies NO35, H2O2 and O2•−31. Studies have 
shown the potential beneficial effects of melatonin in treatment of many chronic diseases while it exhibits low or 
absent toxicity51. In addition, in animal models, melatonin displays protective effects that are NRF2-mediated52.
Herein, primary human melanocytes were treated with pharmacological doses of melatonin or its derivatives. 
We have demonstrated that melatonin, as well as its metabolites (AFMK, 6-OHM, 5-MT, and NAS) protect cells 
from UVB-induced oxidative stress, in accordance with previous studies24, 33. The exposure of melanocytes to 
UVB resulted in formation of intracellular ROS, including NO and H2O2, as well as the reduction of intracellu-
lar glutathione. Pretreatment of melanocytes with melatonin or its metabolites protect against cellular damage 
caused by ROS. They all reduced the levels of ROS (Fig. 5), especially NO and H2O2 (Fig. 1). This process does 
not involve membrane bound melatonin receptors, since melatonin and its metabolites exhibit their antioxidative 
effects even after membrane melatonin receptors were blocked by the receptor antagonist, luzindole (Fig. 5). 
Melatonin receptors (MT1 and MT2) are known to be expressed in human epidermal melanocytes at very low 
levels (Supplementary Fig. S1). Melatonin also promoted glutathione production, which serves as a first line of 
cellular defence against oxidative damage. We have shown that melatonin, AFMK and 6-OH, excluding 5-MT and 
NAS, exhibit slight GSH activation (Fig. 1), while stimulating genes encoding GSH production (Supplementary 
Fig. S2). Despite the correlation between melanin and ROS levels, the latter accumulate and subsequently reduce 
cellular glutathione concentrations in human melanocytes as previously reported9; clearly melatonin plays an 
important role in glutathione regulation37, 53.
Oxidative stress can impair the main repair pathway for UVB-induced DNA damage2, 3. Direct UVB-induced 
DNA lesions (CPD) were present in melanocytes exposed to UVB (Fig. 2a). CPD formation noticeably decreased 
in UVB-irradiated melanocytes treated with melatonin or its metabolites (Fig. 2c,d). Also, melatonin and its 
metabolites enhanced UVB-induced DNA repair (Fig. 2e). Tumor suppressor protein p53 is another important 
regulator of oxidative stress in skin cells. Activation of p53 is one means of reducing oxidative stress in melano-
cytes10 resulting from different stressors, including UVB40. Phosphorylation of p53 is important for activation of 
Figure 7. Melatonin, NAS, 6-OHM, AFMK, and 5-MT treated melanocytes increased NRF2 expression after 
UVB exposure. Melanocytes were exposed to UVB intensities of 0 or 50 mJ/cm2 and immediately treated with 
melatonin or its derivative for 24 h. Cells were further fixed and stained with anti-NRF2 antibody. Stained cells 
were imaged with a fluorescence microscope, fluorescence intensity was analysed using ImageJ software, and 
data are analysed using Graph Pad Prizm after 0 mJ/cm2 (a) and 50 mJ/cm2 (b). In addition, UVB diminishes 
NRF2 expression (insert). Data are presented as percentile of control and were analyzed using t- test, *p < 0.05, 
**p < 0.01.
www.nature.com/scientificreports/
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DNA repair in cells54, especially at the Ser-15 site responsible for DNA damage prevention41, which is stimulated 
by melatonin23, 55. Melatonin and its metabolites augmented the accumulation of UVB-induced p53 in the nucleus 
by increasing phosphorylation of p53 on Ser-15 in melanocytes (Fig. 3), as well as enhanced nucleotide excision 
repair via enhanced interactions between damaged DNA and the NER core factors XPC and XPA (Fig. 4), indi-
cating the protective actions of these compounds against UVB induced cell damage, which is in accordance with 
previous results24.
We have confirmed (Fig. 7, insert) what has been previously described, i.e., UVB reduced the expression of 
NRF2 in melanocytes7, 48. This downregulation was counteracted by treatment with melatonin and its metab-
olites (Fig. 7a,b). Melatonin has often been described as a regulator of NRF256. Melatonin and its metabolites 
also stimulate mRNA expression of antioxidant enzymes and proteins, including catalase, superoxide dismu-
tase, glutathione, NAD(P)H dehydrogenase, glutamylcysteine synthetase and heme oxygenase (Supplementary 
Fig. S2). In this study we have demonstrated that melatonin, as well as its metabolites (AFMK, 6-OHM, 5-MT, 
and NAS) induce NRF2 downstream genes and proteins which further protect primary human melanocytes from 
UVB-induced oxidative stress, similar to their protection in other cells14, 31. The mechanism of this activation is 
mediated by upregulation of NRF2 expression and NRF2- dependant pathway (Fig. 7, and Supplementary Figs S2 
and S3). When siRNA against NRF2 was used, a downregulation of HO-1 and NQO2 was observed despite the 
treatment with the melatonin (Fig. 6). We found that NRF2-activation is important in reduction of UVB-induced 
damage to the skin cells, as shown by others57, 58.
Pre-treatment of melanocytes with melatonin or its metabolites conferred protection against UVB medi-
ated ROS damage. Melatonin and its products stimulated NRF2 activation and expression of NRF2 downstream 
genes and proteins that counteract oxidative stress. Knocking NRF2 gene confirm the mechanism of melatonin in 
NRF2-mediated antioxidative effects on melanocytes. This study demonstrates the benefits of natural products, 
i.e., melatonin and its metabolites, in stimulation of NRF2, an endogenous antioxidative pathway, to prevent del-
eterious effect UVB and UVB-caused oxidative damage. Our data support the protective role of melatonin and it 
metabolites in antioxidant skin defence mechanism. The current results demonstrate the high protection that mel-
atonin and its metabolites, as natural antioxidants, can provide to skin cells against UVB-induced damage. While 
there are differences in the potencies of the protection provided by melatonin and its metabolites, these differences 
are not great given that all melatonin metabolites exhibited strong protective effects against UVB-induced oxidative 
damage to melanocytes. The present study identifies local melatoninergic system as the protector of melanocytes 
against UVB-induced pathology, effects that can be amplified by topical application of melatonin or its derivatives.
Material and Methods
Chemicals. The source of chemicals is described previously24. All chemicals were diluted in pure eth-
anol. AFMK (N1-acetyl-N2-formyl-5-methoxykynuramine) (10005254) was purchased from Cayman 
Chemical Company (Ann Arbor, MI, USA) (catalog number 10005254), while others were purchased from 
Sigma-Aldrich (St. Louis, MO): Melatonin (N-acetyl-5-methoxytryptamine) (M5250), 6-hydroxymela-
tonin (3-(N-acetylaminoethyl)-6-hydroxy-5-methoxyindole) (H0627), N-acetylserotonin (N-acetyl-5-
hydroxytryptamine) (A1824), 5-methoxytryptamine (2-(5-methoxy-1H-indol-3-yl)ethanamine) (286583).
Human tissue samples. The experiments were performed in accordance with relevant guidelines (see 
below) and the experiments were approved by the Institutional Review Board (IRB) at the University of Alabama 
Birmingham. This protocol was identified as not subject to FDA regulation and not Human Subject Research (IRB 
protocol N150915001 – Endocrine Functions of the Skin – revised version). Where necessary it is also covered by 
an exempt protocol category #4 for use of the archival or stored material approved on 7/2/2015 under IRB regis-
tration # IRB00000726 under the title “Neuroendocrinology of the skin and other peripheral organs” E150427002. 
No human subjects were involved in this protocol. However, primary melanocytes were cultured from foreskin 
that would normally be discarded during surgery. Animal subjects were not included in experimental design.
Cell culture. Human epidermal melanocytes (HEMn) are isolated from neonatal foreskin of 
African-American donors and cultured for experiments as previously described59. Cells were grown in mel-
anocyte growth media (MGM) supplemented with melanocyte growth factors (MGF) (Lonza Walkersville Inc, 
Walkersville, MD). For the experiments with UVB the media were replaced with phosphate buffered saline (PBS) 
prior the exposure. Cells in their third passage were used for the experiments and pretreated with melatonin or its 
derivatives 24 h before exposure to UVB after UVB exposure for indicated amount of time. It must be noted that 
melanocytes used for the experiments were darkly pigmented with dendritic morphology that was not affected 
by UVB doses of 25 and 50 mJ/cm2 during relatively short periods of incubation including 3 and 24 h after UVR 
treatment (Supplemental Fig. S3). UV transilluminator 2000 from Bio-RAD Laboratories was used for UVB irra-
diation following protocols and UV spectra reported previously39.
Comet assay. DNA damage and repair were assessed using Comet assay, and detecting levels of CPD dimers 
and p53. The comet assay was performed following the manufacturer’s protocol (Trevigen, Gaithersburg, MD) 
with experimental design as previously described39. Melanocytes were seeded in 12-well plates. Cells were treated 
with melatonin or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for 
24 h. Then, the medium was replaced with 1 × PBS and cells were exposed to UVB 200 mJ/cm2. PBS was removed 
and replaced with fresh medium containing compounds and cells were further incubated for 3 h at 37 °C. After 
detaching, cells were counted and used for the comet assay. Cell suspensions at a density of 1 × 105/ml were com-
bined with molten 1.2% low-melting-point agarose, diluted 1:10, placed onto two frosted slides precoated with 
0.6% normal agarose, and incubated at 4 °C for 30 min. Cells were further digested in lysis solution at 4 °C for 
60 minutes. DNA strand breaks were separated by electrophoresis in alkaline electrophoreses solution (200 mM 
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NaOH, 1 mM EDTA, pH > 13) in horizontal gel electrophoresis slide tray (Comet-10, Thistle Scientific, UK). 
DNA breaks were exposed to alkaline unwinding for 40 min at room temperature after which electrophoresis was 
performed at 25 V for 50 min. Following neutralization in neutralizing buffer (0.4 M Tris, pH7), comets were vis-
ualized by propidium iodide (Sigma-Aldrich, St. Louis, MO) staining. The slides were examined and images were 
captured using Nikon fluorescent microscope and the Leica digital DM 4000b fluorescent microscope equipped 
with image analysis software. Approximately 60 comet images were taken for each condition. DNA damage was 
measured by the tail length using Comet Score software available from http://www.scorecomets.com.
CPD dimers. Following the manufacturer protocol, cells were stained with anti-CPD antibody and nuclei 
were stained red with propidium iodide as previously described24. CPDs in cultured normal melanocytes were 
visualised using immunofluorescence. Briefly, HEMn were plated onto chamber slides, treated with melatonin 
or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for 24 h prior UVB 
exposure, and further for 3 h after the exposure. Following the manufacturer protocol, cells were stained with 
anti-CPD (clone TDM2) (Cosmo Bio Co Ltd., Tokyo, Japan) (dil 1:100) and subsequently with goat anti-mouse 
IgG-FITC (Santa Cruz Biotechnology, Santa Cruz, CA) (1:100). Nuclei were stained red with Vectashield mount-
ing media with propidium iodide (Vector Laboratories, Burlingame, CA). Stained cells were imaged with a fluo-
rescence microscope. Pictures recorded were analysed using ImageJ software (NIH free download).
NRF2 in cultured normal melanocytes was visualised using immunofluorescence. Briefly, HEMn were plated onto 
chamber slides, treated with melatonin or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilu-
tion 5:1,000) for 24 h after UVB exposure. Following the manufacturer protocol, cells were stained with anti-NRF2 
(C20) (sc-722, Santa Cruz Biotech., Santa Cruz, CA) (dil 1:50) and subsequently with Alexa-Fluor 488 goat anti 
rabbit IgG (Invitrogen Molecular Probes, Eugene, Oregon, USA) (1:100). Nuclei were stained red with Vectashield 
mounting media with propidium iodide (Vector Laboratories, Burlingame, CA). Stained cells were imaged with a 
fluorescence microscope. Pictures recorded were analysed using ImageJ software (NIH free download).
Immunofluorescence for p53. Melanocytes were plated onto chamber slides in duplicates. Cells were 
treated with melatonin, or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) 
for 24 h prior UVB exposure and for 3 h for detection of phosphorylated p53 at Ser-1555. Cells were further fixed 
in 4% paraformaldehyde (PFA) for 10 min at room temperature and washed three times with 0.1% Triton X-100 
(BioRad, Hercules, CA) in PBS to permebealize membrane. Blocking was performed in 10% FBS in PBS for 1 h 
at RT after quenching of endogenous peroxidase with 1% H2O2 (BioRad, Hercules, CA) in PBS. Cells were incu-
bated in phospho p53 Ser-15 (9284 Cell Signaling, Danvers, MA) primary antibodies diluted in blocker 1:100 
overnight at 4 °C. The following day cells were washed and incubated with secondary antibody Alexa-Fluor 488 
goat anti-rabbit IgG (Invitrogen Molecular Probes, Eugene, Oregon, USA) diluted in blocker 1:100 for 1 h at RT. 
After washing with PBS, nuclei were stained red with Vectashield mounting media with propidium iodide (Vector 
Laboratories, Burlingame, CA). Stained cells were imaged with a fluorescence microscope. Pictures recorded were 
analysed using ImageJ software (NIH free download).
Reactive oxygen species (ROS) assays. Reactive oxygen species (ROS) assays were used to measure 
ROS levels in HEMn using a fluorescence method as previously described24. Luzindole is used in accordance 
with the literature47. Melanocytes were plated onto 96-well plate. The following day, medium was removed and 
fresh luzindole (Sigma-Aldrich (St. Louis, MO) was added to the cells at the concentration of 50 µM for 1 h. Cells 
are further treated with melatonin or its metabolites at the concentrations of 5 × 10−5 M, 1 × 10−6 M, 1 × 10−8 M, 
1 × 10−10 M, or ethanol (vehicle, dilution 5:1,000) for 1 h. After incubation, cells were washed with cold 1×PBS. 
CM-H2DCFDA dye (Molecular Probes, Invitrogene, Eugene, Oregon) diluted in HEPES at the 5 µM concentra-
tion was added and cells were incubated for additional 30 min. After preincubation with CM-H2DCFDA dye, 
cells were irradiated with 50 mJ/cm2 of UVB and placed in incubator. Thirty minutes post-UVB exposure, cells 
were washed with PBS. The generation of ROS was determined by measuring the fluorescence at 480 nm excita-
tion and 528 nm emission, on SpectraMax M2e instrument (Molecular Devices, Sunnyvale, CA). Data were pre-
sented as percentile of control (EtOH- treated cells).
Oligonucleotide retrieval immunoprecipitation (ORiP). The XPC- and XPA-DNA-interaction was 
tested using oligonucleotide retrieval immunoprecipitation (ORiP) as previously described44. HEMn were treated 
with melatonin or its metabolites for 24 h in complete melanocyte medium and 2% chFBS. Cells were further 
exposed to either 25 mJ/cm2 or 50 mJ/cm2 or non UVB-treated (0 mJ/cm2). After UVB treatment, cells were incu-
bated in fresh medium supplemented with melatonin or its metabolites for an additional 1 or 3 h, before they 
were harvested by scraping and pelleted. Soluble nuclear extract was obtained as previously described44. Synthetic 
oligonucleotides (Molecular Beacons) were assembled to form 5′-biotinylated duplex DNA fragment that pro-
vide a substrate for NER proteins. A 30-nt oligonucleotide, 5′-CTCGTCAGCATCTTCATCATACAGTCAGTG
-3′, was exposed to 10 J/m2 of UVC, annealed and ligated with two oligonucleotides as previously described44. 
After indicated treatments, soluble nuclear extracts (50 µg) were incubated with the biotinylated oligonucleotide 
in streptavidin-coated 96 well plates (Thermo-Scientific) (0.01 nM per well) for 10 minutes at 30 °C. Wells were 
washed with 40 mM Tris-HCl (pH 7.5) containing 0.01% BSA (wash buffer) followed by fixation in 4% para-
formaldehyde. After three washes, 2 µg of either anti-XPA or anti-XPC was added for 1 h at room temperature. 
Detection was accomplished using an HRP-conjugated anti-rabbit secondary antibody (Abcam) for 1 h followed 
by the addition of 1-Step Ultra TMB ELISA Substrate (Pierce) to each well and absorbance measured at 400 nm.
Nitric oxide (NO−) assays. Nitrite levels (NO−) levels were measured using Griess reagent (1% 
sulfanilamide-0.1% N-1-naphthyl-ethylenediamine dihydrochloride in 2.5% phosphoric acid) (Sigma, St. Louis, 
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MO) as previously described60. Melanocytes were seeded onto 60 mm culture plates. Cells were treated with mel-
atonin or its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5:1,000) for 24 h. After 
incubation, cells in cold 1×PBS were irradiated with the UVB intensity of 0 or 25 mJ/cm2. After 30 min of incu-
bation at 37 °C cells were harvested by scraping. Cell pellets were further centrifuged at 3000 g for 5 min, superna-
tant was collected and mixed with an equal amount of Griess reagent. The generation of NO was determined by 
measuring the absorbance at 540 nm in a spectrophotometer of purple azo compound formed from the reaction 
between nitrates formed in samples and Griess reagent. Data were presented as concentration of nitite (µmol) per 
protein amount (mg), and further as percentile of control (EtOH- treated cells).
H2O2 assays. Hydrogen peroxide (H2O2) levels were measured using a luminescence method61. Melanocytes 
were treated with melatonin, its metabolites at the concentration of 5 × 10−5 M, or ethanol (vehicle, dilution 5: 1,000) 
for 24 h. After incubation, cells in 1×PBS were irradiated with the UVB intensity 0 or 25 mJ/cm2. The generation of 
H2O2 was determined by measuring the luminescence of luminol (Sigma, St. Louis, MO) by H2O2 that is released by 
melanocytes 30 min after UV exposure. Aliquots from each dish were mixed with lumiol and horse radish peroxidase 
(Sigma, St. Louis, MO) in respiratory buffer and luminescence was measured in a Turner Luminometer (TD20/20) 
(Promega, Madison, WI). The specificity of the reaction was determined by treating separate UV-irradiated cells 
with 300 units/mL of catalase (Sigma, St. Louis, MO), which degraded H2O2 to H2O and O2. Data were presented as 
concentration of H2O2 (pmol) per 0.1 million cells and further as percentile of control (EtOH treated cells).
Glutathione (GSH) assay. Glutathione (GSH) levels were measured using a fluorometric method60. 
Melanocytes were treated with melatonin, or its metabolites at the concentration of 5 × 10−5 M, or ethanol 
(vehicle, dilution 5:1,000) for 24 h. After incubation, cells were irradiated with the UVB intensity of 0 or 25 mJ/
cm2. After UV exposure cells were further incubated for 1 h at 37 °C. Cells were harvested with trypsiniza-
tion and washed with 1×PBS-EDTA, pH8. After centrifugation, cell pellets were resuspended in ice cold 5% 
meta-phosphoric acid (MPA) (Sigma, St. Louis, MO), sonicated, and centrifuged at 12,000 rpm for 5 min. After 
collection of supernatant, aliquots were taken for protein determination. Supernatant was further mixed with 
1×PBS-EDTA buffer and OPAME (o-phthaldialdehyde (Sigma, St. Louis, MO) in methanol (Fisher, Pittsburgh, 
PA) and borate buffer (potassium-tetraborate, Sigma, St Lois, MO). Mixtures were further aliquoted in 96-well 
plate, incubated for 15 min at RT and GSH levels were determined by measuring the fluorescent signal at 350 nm 
excitation and 420 nm emission, on SpectraMax M2e instrument (Molecular Devices, Sunnyvale, CA). Data were 
presented as percentile of control (EtOH- treated cells).
Reverse transcription polymerase chain reaction (RT-PCR). HEKn cells were cultured for three days 
in 60 mm petri dishes (MidSci, St. Louis, MO). Cells were treated with melatonin, or its metabolites at the con-
centration of 5 × 10−5 M, or ethanol (vehicle, dilution 5: 1,000) for 24 h before UVB exposure and for additional 
3 h post UVB exposure. Cells were exposed to different intensity UVB including: 0, 25, 50 or 75 mJ/cm2. After 
UV exposure cells were further incubated for 1 h at 37 °C. RNA from cells was extracted using Absolutely RNA 
RT–PCR Miniprep kit (Stratagene, La Jolla, CA) as previously described62. Reverse transcription reaction was 
performed using High Capacity cDNA reverse transcription Kit (Applied Biosystems, Foster City, CA). The reac-
tion was performed with LightCycler 480 Probes Master (Roche Applied Science, Indianapolis, IN). The sequence 
and source of primers are shown in Table 1 in supplementary file. Real-time PCR was performed using Kapa 
SYBR Fast qPCR Master Mix (Kapa Biosystems, Boston, MA) performing 35 cycles (95 °C for 15 seconds, 60 °C 
for 30 sec, 72 °C 10 sec) in triplicates. Data was collected with a Roche Light Cycler 480, and the amount of mRNA 
was normalized by comparative Ct method, using B-actin as a housekeeping gene.
siRNA transfection. Melanocytes were transfected with 50 nM NRF2 or scrambled siRNA (Santa Cruz Inc, 
Santa Cruz, CA) using lipofectamine plus (Invitrogen, Eugene, Oregon). Twenty-four hours after transfection, 
cells were treated for an additional 48 h with 5 × 10−5 M melatonin. RNA was isolated and used for gene expres-
sion analysis and, also, whole cell extracts were prepared for protein analysis.
Immunoprecipitation analysis. HEKn cells were lysed in RIPA buffer (Cell Signaling, Beverly, MA, USA) 
on ice for 1 h. After centrifugation (15, 339 g for 20 min at 4 °C), the lysates were incubated with 25 μl of Protein 
A/G PLUS-Agarose beads (Santa Cruz Inc., Santa Cruz, CA) and 1 μg of normal goat serum for 3 h with shaking at 
4 °C, pelleted by centrifugation for 10 min at 4 °C, and incubated overnight at 4 °C on a rocking platform with 25 μl 
of Protein A/G PLUS-Agarose beads and 2 μg of anti MEL1A (sc13186), anti-MEL1A (sc13179), anti-MEL1B 
(sc13177), or anti-MEL1B (sc28453) antibodies (Santa Cruz Inc., Santa Cruz, CA). Immunoprecipitates were col-
lected by centrifugation, washed four times with RIPA buffer, separated by SDS–PAGE, and subjected to immu-
noblotting, as described previously62. The primary antibodies used for immunoblotting were goat polyclonal 
antibodies against MEL1A or MEL1B. The secondary antibody used was HRP anti-goat IgG.
Experiments were repeated three times and analysed using Student’s t-test or anova (*) and appropriate post 
hoc test, using Microsoft Excel and Prism 4.00 (GraphPad Prism 4 Software) and representative graphs have been 
prepared. Statistically significant differences are denoted in the figures and corresponding figure legends.
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